Evaluating Breast Cancer Patient-Specific Metastasis Severity at Bone Site Using In Vitro Models.

Area of Science:

• Oncology
• Biotechnology
• Cell Biology

Background:

• Stage IV breast cancer often metastasizes to bone, significantly reducing survival rates.
• Current treatments for bone metastatic breast cancer are limited, necessitating advanced in vitro models for drug development.
• Previous work established a 3D nanoclay in vitro model for bone metastatic breast cancer.

Purpose of the Study:

• To evaluate an in vitro model's ability to differentiate metastasis severity across eight patient-derived breast cancer cell lines.
• To assess the effects of Rhodiola crenulata extract on these patient-derived bone metastatic cell lines.
• To investigate the impact of these cell lines on Wnt signaling pathways via ET-1 and DKK-1.

Main Methods:

• Utilized a 3D nanoclay in vitro model with eight patient-derived breast cancer cell lines.
• Cultured cells in a bone metastatic (BM) environment and treated with Rhodiola crenulata extract.
• Analyzed cell line characteristics, tumor formation in bone microenvironment, and Wnt signaling pathway modulation.

Main Results:

• The in vitro model successfully distinguished metastasis severity among patient-derived cell lines, maintaining subtype-specific characteristics.
• Rhodiola crenulata induced cytotoxicity in most patient-derived BM cultures, with variations observed.
• Differences in Wnt signaling pathway activity (ET-1, DKK-1) were identified across cell lines and subtypes.

Conclusions:

• A patient-derived bone metastatic breast cancer model was successfully established for personalized drug screening.
• The model can assess metastasis severity within breast cancer subtypes for individual patients.
• This platform offers a precise tool for developing targeted therapies for advanced-stage breast cancer.